When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Artificial intelligence has the potential to transform cancer research. But AI is only as powerful as the data behind it. The Cancer Research Institute's Discovery Engine is building…
Chromosomes, FISH, and Why Cytogenetics Matter in CLL This episode explains how chromosome analysis helps predict prognosis in chronic lymphocytic leukemia, starting with the basics of how chromosomes…
Join us for an informative webinar featuring Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients…
Previous attempts to treat Christine’s Chronic Lymphocytic Leukemia (CLL) had failed. She participated in a clinical trial and subsequently went through a CAR T-cell transplant at the NCI-designated…
In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
